MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Twist Bioscience Corp

Geschlossen

BrancheGesundheitswesen

42.96 -4.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

42.36

Max

43.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-48M

-27M

Verkäufe

3M

99M

Gewinnspanne

-27.41

Angestellte

979

EBITDA

3.2M

-21M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

-3.94% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

2. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

669M

2.5B

Vorheriger Eröffnungskurs

47.83

Vorheriger Schlusskurs

42.96

Nachrichtenstimmung

By Acuity

50%

50%

142 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Jan. 2026, 18:41 UTC

Ergebnisse

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24. Jan. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Jan. 2026, 09:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

24. Jan. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Jan. 2026, 09:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

24. Jan. 2026, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23. Jan. 2026, 22:30 UTC

Market Talk

Global Equities Roundup: Market Talk

23. Jan. 2026, 22:30 UTC

Market Talk

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23. Jan. 2026, 22:03 UTC

Ergebnisse

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. Jan. 2026, 21:52 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23. Jan. 2026, 21:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

23. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

23. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. Jan. 2026, 21:39 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23. Jan. 2026, 21:12 UTC

Ergebnisse

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23. Jan. 2026, 20:31 UTC

Ergebnisse

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. Jan. 2026, 20:12 UTC

Market Talk

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23. Jan. 2026, 20:07 UTC

Market Talk

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23. Jan. 2026, 19:36 UTC

Market Talk

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23. Jan. 2026, 19:30 UTC

Market Talk
Ergebnisse

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23. Jan. 2026, 19:18 UTC

Market Talk

Gold and Silver Step Up to More Records -- Market Talk

23. Jan. 2026, 19:15 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23. Jan. 2026, 18:53 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23. Jan. 2026, 18:21 UTC

Ergebnisse

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23. Jan. 2026, 18:19 UTC

Market Talk

Intel Seen as Increasingly Confident on Demand -- Market Talk

23. Jan. 2026, 17:59 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23. Jan. 2026, 17:57 UTC

Market Talk

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23. Jan. 2026, 17:57 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Twist Bioscience Corp Prognose

Kursziel

By TipRanks

-3.94% Nachteil

12-Monats-Prognose

Durchschnitt 41.25 USD  -3.94%

Hoch 43 USD

Tief 39 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Twist Bioscience Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

31.56 / 38.6884Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

142 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat